Does the rs12740374 protective SORT1 allele increase hepatic LDL clearance?

The noncoding regulatory variant rs12740374 at the 1p13.3 locus is a key genetic determinant of cardiovascular health, acting as a critical regulator of hepatic lipid metabolism.

Molecular mechanisms of SORT1 regulation

• Transcription factor binding: The minor, protective T allele of rs12740374 creates a high-affinity binding motif for the CCAAT/enhancer-binding protein alpha (C/EBPα) transcription factor in hepatocytes.
• Enhanced gene expression: Direct binding of C/EBPα drives robust, liver-specific enhancer activity, resulting in up to a 10- to 12-fold increase in hepatic SORT1 (sortilin) mRNA and protein expression.

Hepatic clearance and lipoprotein secretion

• LDLR-independent clearance: Sortilin functions as a cell-surface endocytic receptor that binds circulating LDL particles, facilitating their internalization and lysosomal degradation independently of the classical LDL receptor (LDLR) pathway.
• Secretion restriction: Elevated hepatic SORT1 also restricts the cellular secretion of apolipoprotein B (ApoB)-containing very-low-density lipoproteins (VLDL), which are the metabolic precursors to circulating LDL.

Impact of lacking the protective allele

• Elevated lipid metrics: Lacking this protective T allele (carrying the major G allele) reduces hepatic SORT1 expression, thereby impairing LDL clearance and increasing VLDL secretion.
• Quantitative changes: This reduction in clearance is associated with higher circulating LDL cholesterol (LDL-C)—with each copy of the protective allele typically lowering LDL-C by 6 to 8 mg/dL.
• Atherogenic particle concentration: Lacking the protective variant consequently leads to increased plasma concentrations of ApoB and higher LDL particle numbers (LDL-P), particularly small, dense LDL.

Bottom line

• The rs12740374 protective T allele creates a C/EBPα binding site that upregulates hepatic SORT1 to enhance LDL clearance and restrict VLDL secretion; conversely, lacking this allele impairs these pathways, resulting in significantly higher circulating LDL-C, ApoB, and LDL particle numbers.